<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Knop, Filip K.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">GLP-1 Receptor Agonists and DPP-4 Inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">24-26</style></pages><abstract><style  face="normal" font="default" size="100%">Incretins are hormones that stimulate insulin secretion in response to meals. Glucagon-like peptide-1 (GLP-1), an incretin secreted by enteroendocrine L-cells, stimulates insulin release, suppresses glucagon secretion, and reduces appetite, leading to the lowering of blood glucose. This article presents an overview of incretin-based therapies, and discussed the differences between the GLP-1RAs, as well as between dipeptidyl peptidase-4 inhibitors.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>